NewEdge Advisors LLC reduced its holdings in Sanofi (NASDAQ:SNY – Free Report) by 40.0% in the 2nd quarter, Holdings Channel reports. The fund owned 46,489 shares of the company’s stock after selling 31,012 shares during the quarter. NewEdge Advisors LLC’s holdings in Sanofi were worth $1,983,000 at the end of the most recent quarter.
Several other institutional investors and hedge funds have also modified their holdings of the business. Bank of America Corp DE lifted its holdings in shares of Sanofi by 11.0% in the first quarter. Bank of America Corp DE now owns 9,484,350 shares of the company’s stock valued at $456,956,000 after purchasing an additional 940,342 shares in the last quarter. Franklin Resources Inc. grew its holdings in shares of Sanofi by 29.7% in the 4th quarter. Franklin Resources Inc. now owns 5,100,097 shares of the company’s stock valued at $247,151,000 after acquiring an additional 1,168,339 shares in the last quarter. Mondrian Investment Partners LTD increased its position in shares of Sanofi by 23.5% in the fourth quarter. Mondrian Investment Partners LTD now owns 4,495,348 shares of the company’s stock valued at $217,845,000 after acquiring an additional 856,742 shares during the last quarter. Natixis Advisors LLC increased its position in shares of Sanofi by 3.9% in the fourth quarter. Natixis Advisors LLC now owns 3,234,911 shares of the company’s stock valued at $156,764,000 after acquiring an additional 121,530 shares during the last quarter. Finally, Royal Bank of Canada raised its holdings in Sanofi by 17.5% during the first quarter. Royal Bank of Canada now owns 3,155,080 shares of the company’s stock worth $152,011,000 after acquiring an additional 470,882 shares in the last quarter. 14.03% of the stock is currently owned by institutional investors and hedge funds.
Analyst Upgrades and Downgrades
A number of equities research analysts have recently issued reports on SNY shares. Wall Street Zen raised shares of Sanofi from a “hold” rating to a “buy” rating in a report on Saturday, August 29th. Morgan Stanley set a $49.00 price objective on Sanofi in a research report on Wednesday, July 8th. Weiss Ratings downgraded Sanofi from a “hold (c-)” rating to a “sell (d)” rating in a report on Monday, August 3rd. HSBC reissued a “buy” rating on shares of Sanofi in a research report on Thursday, September 10th. Finally, Royal Bank Of Canada began coverage on shares of Sanofi in a report on Tuesday, September 8th. They set a “sector perform” rating for the company. Two equities research analysts have rated the stock with a Strong Buy rating, three have given a Buy rating, ten have issued a Hold rating and one has given a Sell rating to the company. According to MarketBeat.com, the company presently has a consensus rating of “Hold” and a consensus target price of $49.50.
Sanofi Trading Down 1.5%
SNY opened at $42.48 on Friday. Sanofi has a fifty-two week low of $40.89 and a fifty-two week high of $52.68. The company has a debt-to-equity ratio of 0.21, a current ratio of 0.99 and a quick ratio of 0.64. The company’s 50-day moving average is $43.92 and its 200 day moving average is $44.41. The firm has a market capitalization of $102.99 billion, a PE ratio of 22.24, a P/E/G ratio of 1.30 and a beta of 0.35.
Sanofi (NASDAQ:SNY – Get Free Report) last posted its quarterly earnings data on Thursday, July 30th. The company reported $2.41 EPS for the quarter. The firm had revenue of $13.36 billion during the quarter. Sanofi had a net margin of 8.66% and a return on equity of 14.19%. The company’s quarterly revenue was up 16.0% on a year-over-year basis. During the same quarter last year, the business posted $3.24 EPS. As a group, research analysts predict that Sanofi will post 5.07 earnings per share for the current fiscal year.
Sanofi Company Profile
Sanofi is a global healthcare company headquartered in France that develops, manufactures and markets prescription medicines and vaccines. Its portfolio serves patients across areas including immunology, rare diseases, rare blood disorders, neurology, oncology and inflammatory conditions, as well as other specialty-care and general-medicine categories.
The company is also a major vaccine producer through its vaccines business, which supplies products for diseases such as influenza, polio, pertussis, meningitis and dengue.
Read More
- Five stocks we like better than Sanofi
- J.B. Hunt’s Stock Plunges After Market Misprices Profit Warning
- 2 Stocks Breaking Out Post-FOMC With One Thing in Common
- Lennar’s Q3 Miss Hides a Stronger Operating Story Beneath the Housing Slump
- These 3 Stocks Are Drawing Insider Buyers for Very Different Reasons
Want to see what other hedge funds are holding SNY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Sanofi (NASDAQ:SNY – Free Report).
Receive News & Ratings for Sanofi Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sanofi and related companies with MarketBeat.com's FREE daily email newsletter.
